A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

被引：0

作者：

Nannis, Gabriel N. ^{[1
]}

Griffiths, Elizabeth A. ^{[2
]}

Savona, Michael R. ^{[3
]}

Odenike, Olatoyosi ^{[4
]}

Roboz, Gail J. ^{[5
]}

O'Connell, Casey L. ^{[6
]}

Dillingham, Jacqueline ^{[7
]}

Wason, Prieya ^{[7
]}

Zhu, Lixia ^{[7
]}

Chan, Danna ^{[7
]}

Keer, Harold N. ^{[7
]}

Oganesian, Aram ^{[7
]}

Dao, Kim-Hien ^{[7
]}

DiNardo, Courtney D. ^{[8
]}

机构：

[1] Stanford Univ, Div Hematol, Dept Med, Sch Med, Stanford, CA USA

[2] Roswell Pk Comprehens Canc Ctr, New York, NY USA

[3] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA

[4] Univ Chicago, Chicago, IL USA

[5] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[6] Univ Southern Calif, USC Keck Sch Med, Los Angeles, CA USA

[7] Astex Pharmaceut Inc, Pleasanton, CA USA

[8] Univ Texas MD, Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1245

引用

页数：5

共 50 条

[11] Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Issa, Ghayas C.
Cuglievan, Branko
DiNardo, Courtney D.
Short, Nicholas J.
McCall, David
Gibson, Amber
Nunez, Cesar
Garcia, Miriam B.
Roth, Michael
Bidikian, Aram
Pike, Allison
Tan, Sheila
Kammerer, Brianna
Yilmaz, Musa
Kadia, Tapan M.
Pemmaraju, Naveen
Ohanian, Maro
Daver, Naval
Jabbour, Elias
Borthakur, Gautam
Ravandi, Farhad
Garcia-Manero, Guillermo
Andreeff, Michael
Kantarjian, Hagop M.
BLOOD, 2023, 142
[12] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Briski, Robert
Short, Nicholas J.
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney D.
Yilmaz, Musa
Valero, Yesid Alvarado
Vaughan, Kenneth
Pierce, Sherry
Montalbano, Kathryn
Mullin, Jillian
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Ravandi, Farhad
BLOOD, 2023, 142
[13] Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study
Bazinet, Alexandre
Kantarjian, Hagop M.
Ravandi, Farhad
Short, Nicholas J.
Daver, Naval
Ohanian, Maro
Yilmaz, Musa
Chien, Kelly S.
Maiti, Abhishek
DiNardo, Courtney D.
Ishizawa, Jo
Masarova, Lucia
Bull-Linderman, Debra
Borthakur, Gautam
Jabbour, Elias
Garcia-Manero, Guillermo
Kadia, Tapan M.
BLOOD, 2023, 142
[14] Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy
Erba, Harry P.
LEUKEMIA RESEARCH, 2015, 39 (02) : 183 - 191
[15] Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Pratz, Keith W.
Cherry, Mohamad
Altman, Jessica K.
Cooper, Brenda W.
Podoltsev, Nikolai A.
Cruz, Jose Carlos
Lin, Tara L.
Schiller, Gary J.
Jurcic, Joseph G.
Asch, Adam
Wu, Ruishan
Hill, Jason E.
Gill, Stanley C.
James, Angela J.
Rich, Elizabeth Shima
Hasabou, Nahla
Perl, Alexander E.
Levis, Mark J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4236 - +
[16] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
Atluri, Himachandana
Maiti, Abhishek
Sasaki, Koji
Daver, Naval
Alvarado, Yesid
Hossain, Md Feroz
Wang, Xuemei
Pemmaraju, Naveen
Takahashi, Koichi
Borthakur, Gautam
Ferrajoli, Alessandra
Short, Nicholas
Abbas, Hussein A.
Ravandi, Farhad
Jabbour, Elias
Andreeff, Michael
Garcia-Manero, Guillermo
Kantarjian, Hagop
Konopleva, Marina
DiNardo, Courtney D.
BLOOD, 2022, 140 : 6170 - 6172
[17] A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
Pratz, Keith W.
Cherry, Mohamad
Altman, Jessica K.
Cooper, Brenda W.
Cruz, Jose Carlos
Jurcic, Joseph G.
Levis, Mark
Lin, Tara
Perl, Alexander E.
Podoltsev, Nikolai A.
Schiller, Gary J.
Hill, Jason E.
James, Angela
Lu, Qiaoyang
Tiu, Ramon V.
BLOOD, 2020, 136
[18] Lower-intensity CPX-351+venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
Uy, Geoffrey L.
Pullarkat, Vinod A.
Baratam, Praneeth
Stuart, Robert K.
Walter, Roland B.
Winer, Eric S.
Faderl, Stefan
Chandrasekaran, Vijayalakshmi
Wang, Qi
Chakravarthy, Divya
Cheung, Ronald
Lin, Tara L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[19] A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)
Garcia-Manero, Guillermo
Griffiths, Elizabeth A.
Roboz, Gail J.
Busque, Lambert
Wells, Richard A.
Odenike, Olatoyosi
Steensma, David P.
Yee, Karen W. L.
Faderl, Stefan
Amrein, Philip C.
Michaelis, Laura C.
Kantarjian, Hagop M.
Oganesian, Aram
Lowder, James N.
Azab, Mohammad
Savona, Michael R.
BLOOD, 2017, 130
[20] Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
Perez, Jorge M. Ramos
Tinajero, Jose
Ngo, Dat
Zhang, Jianying
Koller, Paul B.
Agrawal, Vaibhav
Pourhassan, Hoda
Al Malki, Monzr M.
Salhotra, Amandeep
Ali, Haris
Aribi, Ahmed
Sandhu, Karamjeet S.
Arslan, Shukaib
Otoukesh, Salman
Amanam, Idoroenyi
Artz, Andrew S.
Becker, Pamela S.
Stewart, Forrest M.
Smith, Eileen P.
Curtin, Peter
Forman, Stephen J.
Nakamura, Ryotaro
Pullarkat, Vinod A.
Marcucci, Guido
Stein, Anthony S.
Aldoss, Ibrahim
Ball, Brian J.
BLOOD, 2022, 140 : 9039 - 9040

← 1 2 3 4 5 →